BioMarin Reports Third Quarter 2026 Financial and Operating Results

BioMarin’s Q3 2026 revenue rose 32% year over year to $1.025 billion, while GAAP net loss widened to $123 million from $31 million and non-GAAP income increased to $45 million from $22 million. The company lowered its 2026 revenue midpoint to $3.85 billion from $3.90 billion and non-GAAP diluted EPS guidance to $2.80–$3.10 from $4.90–$5.10, citing order-timing uncertainty and approximately $403 million in expected full-year pre-tax charges tied to Alesta and the BMN 450 license. BioMarin also reported a May 30, 2027 FDA action date for VOXZOGO in hypochondroplasia and added an investigational Fabry disease asset to its pipeline.

Analysis

The earnings signal is weaker than the 32% headline suggests: acquired Amicus products explain much of the reported growth, while the full-year revenue midpoint fell only modestly and the EPS midpoint was cut sharply. The EPS reset reflects $403M of forecast Alesta and BMN 450 charges, so it is not a clean read-through to recurring product economics; however, acquisition and licensing spend is real capital allocation, and BMRN’s added debt and interest burden make the balance-sheet cost of its pipeline strategy relevant. Q3 interest expense and the lower cash balance reinforce that scrutiny.

The order-timing explanation is plausible but creates near-term concentration risk: management attributes the guide change to multiple orders from one international customer. A Q4 catch-up would support timing rather than demand; further slippage or cancellation would expose underlying product growth. Verify order status and product-level demand on the call, especially since VIMIZIM growth also benefited from order timing. POMBILITI + OPFOLDA’s uptake partly benefiting from supply constraints elsewhere is also less durable if competitors restore supply.

For BMRN, near-term catalysts are Q4 order conversion and integration/synergy delivery; 2027 brings VOXZOGO regulatory decisions, while most newly added pipeline assets have longer-dated, binary value. The Ascendis settlement gives BMRN royalties on specified Yuviwel sales through May 2030, while removing a litigation overhang for ASND; neither the royalty economics nor future sales are quantified here. Contrarian point: treating the EPS cut as entirely an operating deterioration overstates the signal, but treating it as purely non-cash noise understates the acquisition cost and leverage. No valuation data supports a high-conviction outright short.

Key Decisions for Investors

• Keep BMRN underweight versus a diversified biotech benchmark into the conference call; do not chase the revenue beat. Reassess if management confirms the delayed international orders are booked for Q4 and maintains product-level demand trends.
• Use the call to test whether the revenue revision is timing or demand: seek customer/order status, product-level Q4 assumptions, and any change in receivables or inventory. Further order slippage or a product-growth/guidance reduction would falsify the benign timing thesis and strengthen the underweight.
• Track BMRN debt maturities, interest expense, and cash generation alongside the promised Amicus synergies. If integration costs persist or operating cash flow weakens, the balance-sheet burden could offset portfolio growth; evidence of synergy delivery and debt reduction would weaken the cautious stance.
• Treat ASND as a watch rather than a new trade: the settlement removes a litigation uncertainty and creates a BMRN royalty obligation, but the article provides no sales or royalty forecast to quantify either company's earnings impact.